Law360, New York (April 10, 2013, 12:09 PM EDT) -- On March 21, 2013, Virginia Gov. Bob McDonnell signed into law the nation’s first state law concerning substitution of biosimilars. The law’s requirements that pharmacists give notice of substitution to prescribers and give notice of retail costs to patients differ significantly from the state’s existing law applicable to substitution of small-molecule drugs.
This article analyzes the Virginia law, examines the principles set forth by the Biotechnology Industry Organization (BIO) on biosimilar substitution and reviews biosimilar substitution legislation pending in other states.
Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.